![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
March of Dimes, White Plains, NY 10605 and Albert Einstein College of Medicine, NY 10461
3To whom correspondence should be addressed. E-mail: ngreen{at}modimes.org.
Based on animal studies, epidemiologic studies and intervention trials, maternal folic acid is known to be protective for neural tube defects (NTD), primarily spina bifida and anencephalus. To reduce the risk of NTD, the U.S. Food and Drug Administration mandated that all enriched cereal grain products be fortified with folic acid as of January 1998. Recent data demonstrate that this public health action is associated with increased folate blood levels among U.S. women of childbearing age and that the national rate of spina bifida has decreased by 20%. Rates of anencephaly appear not to have declined. Epidemiologic data on use of folate and folate antagonists have also implicated folic acid in prevention of other birth defects such as facial clefts and cardiac and limb defects. Dietary folic acid is likely to be inadequate for maximal protection against NTD. Because about half of pregnancies in the U.S. are unplanned, according to the March of Dimes, birth defect prevention includes a recommended daily dose of 400 µg synthetic folic acid for women of childbearing age. Uniform compliance is estimated to decrease the incidence of NTD by up to 70%. This could reduce the overall incidence from 2 to 0.6 per 1000 pregnancies and prevent disease in 
2000 babies per year in the U.S. Four thousand micrograms of folic acid per day is recommended for women with previous pregnancies affected by NTD.
KEY WORDS: • folate • folic acid • neural tube defects • birth defects • spina bifida • ancencephalus
This article has been cited by other articles:
|
|
 |
|
  M. Ryan-Harshman and W. Aldoori Folic acid and prevention of neural tube defects Can Fam Physician, January 1, 2008; 54(1): 36 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J Benevenga Consideration of betaine and one-carbon sources of N5-methyltetrahydrofolate for use in homocystinuria and neural tube defects Am. J. Clinical Nutrition, April 1, 2007; 85(4): 946 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fenech The Genome Health Clinic and Genome Health Nutrigenomics concepts: diagnosis and nutritional treatment of genome and epigenome damage on an individual basis Mutagenesis, July 1, 2005; 20(4): 255 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Clifford, E. M. Noceti, A. Block-Joy, T. Block, and G. Block Erythrocyte Folate and Its Response to Folic Acid Supplementation Is Assay Dependent in Women J. Nutr., January 1, 2005; 135(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Ortega, A. M. Requejo, A. M. Lopez-Sobaler, B. Navia, M. C. Mena, B. Basabe, and P. Andres Smoking and Passive Smoking as Conditioners of Folate Status in Young Women J. Am. Coll. Nutr., August 1, 2004; 23(4): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. O. Marasas, R. T. Riley, K. A. Hendricks, V. L. Stevens, T. W. Sadler, J. Gelineau-van Waes, S. A. Missmer, J. Cabrera, O. Torres, W. C. A. Gelderblom, et al. Fumonisins Disrupt Sphingolipid Metabolism, Folate Transport, and Neural Tube Development in Embryo Culture and In Vivo: A Potential Risk Factor for Human Neural Tube Defects among Populations Consuming Fumonisin-Contaminated Maize J. Nutr., April 1, 2004; 134(4): 711 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]
|
|
